What was most surprising in this case was not that one of the athletic participants in the tourney was taking a performance enhancing drug. That sort of thing honestly happened all the time, and they tried to catch it where they could. No, the most surprising was the five myocardial infarctions he'd endured without dying yet. Considering the statistical probability of surviving a heart attack was one in three, it made for impressive odds that he'd managed to cheat fate as much as he had. Those odds significantly improve when one is actually in a hospital, and the participant, one Nemuri Eigo, had been present ever since his first. Shuu, currently in the lab, was analyzing his blood sample herself in this unusual case. Somehow his blood was a combination of an antihemorrhagic and an anticoagulant. The anticoagulant made sense. Blood thinners allowed the blood to move freely through veins and arteries by preventing the very clotting that was having a hand in causing the man's heart attacks. To make matters worse he seemed to be going through cycles of vasoconstriction and vasodiolation, making prediction of future heart attacks during the life cycle of this drug much more difficult. A lot wasn't making sense, but the most rudimentary ones was that an antihemorrhagic and an anticoagulant seemed to be present at the same time in his bloodstream. The only thing she could think of was that the antihemorrhagic was a byproduct created in the blood stream...but how?
Slipping the test tube into the centerfuge, she leaned back and crossed her arms. When the body was being used heavily, it released glucose into the blood stream for the cells to convert into a chemical compound that basically was energy. Perhaps this chemical in the drug bonded with the glucose. As that was being metabolized into Adenosine triphosphate--or ATP--to create energy for the body, the chemical reaction was interacting with the metabolic process, fueling it to happen much faster, to provide more energy for the user. However, in that act, a chemical byproduct was being created, a kind of 'drug waste'. As the unwanted particles created were being discarded back into the blood stream, the new chemical formation matured directly in the blood stream to create an antihemorrhagic, which encouraged clotting. Those clots would cause heart attacks, especially in time with vasoconstriction. If she was right, then the side effects of heart attacks wouldn't show up until a few hours after the body was being used heavily to create that ATP creation overdrive. The anticoagulant and the vasodiolator, both originally included for performance purposes, actually had the good fortune to keep it from being fatal.
Nonetheless, if her research proved correct, then she needed to find a chemical compound that would specifically break up the antihemorrhagic byproduct, as well as the vasoconstrictor, as both clotting and vasoconstriction were major contributing factors towards a myocardial infarction on their own, much less working in tandem. Since the vasoconstrictor was already in his system the best counteractant was additional vasodiolators, that was easy enough. The real issue was the antihemorrhagic. While conventional medicine would not help, she learned that by using a mild electrical charge of chakra targetting specifically this compound in the bloodstream, she could break up the unusual compound not normally seen in nature.
After treatment the heart attacks stopped, and it took another twelve hours for his body to finish metabolizing the drug-- which she'd nicknamed Lightning because it acted not unlike a lightning strike on one's cardiopulmonary systems--but he survived without further complications. Now that she knew what to look for, screening for Lightning was an easy enough process, certain additive compounds showed up like a glowing indicator light.
A brief writeup on the outcome fired off to both the Tower and local files finished off the case, finally solved after an entire day of research and testing.
[MFT]
WC: 648
Slipping the test tube into the centerfuge, she leaned back and crossed her arms. When the body was being used heavily, it released glucose into the blood stream for the cells to convert into a chemical compound that basically was energy. Perhaps this chemical in the drug bonded with the glucose. As that was being metabolized into Adenosine triphosphate--or ATP--to create energy for the body, the chemical reaction was interacting with the metabolic process, fueling it to happen much faster, to provide more energy for the user. However, in that act, a chemical byproduct was being created, a kind of 'drug waste'. As the unwanted particles created were being discarded back into the blood stream, the new chemical formation matured directly in the blood stream to create an antihemorrhagic, which encouraged clotting. Those clots would cause heart attacks, especially in time with vasoconstriction. If she was right, then the side effects of heart attacks wouldn't show up until a few hours after the body was being used heavily to create that ATP creation overdrive. The anticoagulant and the vasodiolator, both originally included for performance purposes, actually had the good fortune to keep it from being fatal.
Nonetheless, if her research proved correct, then she needed to find a chemical compound that would specifically break up the antihemorrhagic byproduct, as well as the vasoconstrictor, as both clotting and vasoconstriction were major contributing factors towards a myocardial infarction on their own, much less working in tandem. Since the vasoconstrictor was already in his system the best counteractant was additional vasodiolators, that was easy enough. The real issue was the antihemorrhagic. While conventional medicine would not help, she learned that by using a mild electrical charge of chakra targetting specifically this compound in the bloodstream, she could break up the unusual compound not normally seen in nature.
After treatment the heart attacks stopped, and it took another twelve hours for his body to finish metabolizing the drug-- which she'd nicknamed Lightning because it acted not unlike a lightning strike on one's cardiopulmonary systems--but he survived without further complications. Now that she knew what to look for, screening for Lightning was an easy enough process, certain additive compounds showed up like a glowing indicator light.
A brief writeup on the outcome fired off to both the Tower and local files finished off the case, finally solved after an entire day of research and testing.
[MFT]
WC: 648